TRV GP III, LLC - Q2 2021 holdings

$573 Million is the total value of TRV GP III, LLC's 7 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .

 Value Shares↓ Weighting
RVMD  REVOLUTION MEDICINES, INC.$175,333,000
-30.8%
5,524,0310.0%30.61%
-4.5%
PLRX  PLIANT THERAPEUTICS, INC.$170,036,000
-26.0%
5,839,1600.0%29.69%
+2.2%
NRIX SellNURIX THERAPEUTICS, INC.$90,800,000
-35.2%
3,422,549
-24.1%
15.85%
-10.6%
FULC  FULCRUM THERAPEUTICS, INC.$62,484,000
-11.0%
5,962,2020.0%10.91%
+22.8%
DBTX  DECIBEL THERAPEUTICS, INC.$27,001,000
-24.3%
3,139,6850.0%4.71%
+4.5%
VYGR  VOYAGER THERAPEUTICS, INC.$26,396,000
-12.3%
6,391,1760.0%4.61%
+21.0%
JNCE  JOUNCE THERAPEUTICS, INC.$20,732,000
-33.8%
3,048,7800.0%3.62%
-8.6%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • Mark Levin #1
  • Kevin P. Starr #2
  • Robert I. Tepper #3
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-08-11
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
VOYAGER THERAPEUTICS, INC.22Q1 202374.0%
JOUNCE THERAPEUTICS, INC.20Q3 202224.5%
PLIANT THERAPEUTICS, INC.14Q3 2023100.0%
FULCRUM THERAPEUTICS, INC.14Q4 202243.8%
REVOLUTION MEDICINES, INC.12Q4 202253.8%
DECIBEL THERAPEUTICS, INC.10Q2 202366.3%
NEON THERAPEUTICS, INC.8Q1 202041.1%
NURIX THERAPEUTICS, INC.8Q2 202217.7%
RELAY THERAPEUTICS, INC.2Q4 202037.7%
MYOKARDIA, INC.2Q1 201822.1%

View TRV GP III, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-13
13F-HR2023-08-10
13F-HR2023-05-12
13F-HR2023-02-14
42023-02-06
42023-02-01
42023-01-31
42023-01-26
42023-01-24

View TRV GP III, LLC's complete filings history.

Compare quarters

Export TRV GP III, LLC's holdings